OncoMatch/Clinical Trials/NCT06880523
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Is NCT06880523 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including STRIDE (durvalumab + tremelimumab) and Durvalumab for hepatocellular carcinoma.
Treatment: STRIDE (durvalumab + tremelimumab) · Durvalumab · Lenvatinib — The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE B (NOT ELIGIBLE FOR LOCOREGIONAL THERAPY), BCLC STAGE C (BCLC)
Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PD-1 inhibitor (durvalumab)
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Cannot have received: PD-L1 inhibitor (durvalumab)
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Cannot have received: anti-CTLA-4 therapy (tremelimumab)
Any previous treatment with ... anti-CTLA4, including tremelimumab
Lab requirements
Liver function
child-pugh score class a or b7 based on low albumin (albumin 25-27 g/l) only
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06880523 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage BCLC STAGE B (NOT ELIGIBLE FOR LOCOREGIONAL THERAPY) or BCLC STAGE C is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages